Loading...

Myovant Sciences

DB:71M
Snowflake Description

Moderate growth potential and slightly overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
71M
DB
$1B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women’s health and endocrine diseases. The last earnings update was 74 days ago. More info.


Add to Portfolio Compare Print
  • Myovant Sciences has significant price volatility in the past 3 months.
71M Share Price and Events
7 Day Returns
-5.5%
DB:71M
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
-0.1%
DB:71M
-10.2%
DE Biotechs
-6%
DE Market
71M Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Myovant Sciences (71M) -5.5% -17.9% -7.7% -0.1% - -
DE Biotechs -2.4% 3.8% -8.6% -10.2% 51.2% 10.1%
DE Market 1.8% 6% 7.8% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • 71M outperformed the Biotechs industry which returned -10.2% over the past year.
  • 71M outperformed the Market in Germany which returned -6% over the past year.
Price Volatility
71M
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Myovant Sciences undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Myovant Sciences to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Myovant Sciences.

DB:71M Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 4 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 9.3%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:71M
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6.7%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.448 (1 + (1- 19%) (7.28%))
1.357
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.36
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.357 * 6.65%)
9.25%

Discounted Cash Flow Calculation for DB:71M using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Myovant Sciences is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:71M DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 9.25%)
2019 -244.50 Analyst x2 -223.79
2020 -292.00 Analyst x2 -244.63
2021 -285.00 Analyst x2 -218.55
2022 -228.00 Analyst x1 -160.03
2023 90.00 Analyst x1 57.82
2024 511.00 Analyst x1 300.48
2025 604.49 Est @ 18.29% 325.35
2026 682.31 Est @ 12.87% 336.13
2027 744.27 Est @ 9.08% 335.60
2028 792.09 Est @ 6.42% 326.92
Present value of next 10 years cash flows $835.30
DB:71M DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $792.09 × (1 + 0.23%) ÷ (9.25% – 0.23%)
$8,796.49
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $8,796.49 ÷ (1 + 9.25%)10
$3,630.52
DB:71M Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $835.30 + $3,630.52
$4,465.82
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $4,465.82 / 70.81
$63.07
DB:71M Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:71M represents 0.86781x of NYSE:MYOV
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.86781x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 63.07 x 0.86781
€54.73
Value per share (EUR) From above. €54.73
Current discount Discount to share price of €16.61
= -1 x (€16.61 - €54.73) / €54.73
69.7%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Myovant Sciences is available for.
Intrinsic value
>50%
Share price is €16.61 vs Future cash flow value of €54.73
Current Discount Checks
For Myovant Sciences to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Myovant Sciences's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Myovant Sciences's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Myovant Sciences's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Myovant Sciences's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:71M PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-3.84
NYSE:MYOV Share Price ** NYSE (2019-04-18) in USD $19.14
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Myovant Sciences.

DB:71M PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NYSE:MYOV Share Price ÷ EPS (both in USD)

= 19.14 ÷ -3.84

-4.99x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Myovant Sciences is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Myovant Sciences is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Myovant Sciences's expected growth come at a high price?
Raw Data
DB:71M PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.99x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
41.1%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Myovant Sciences, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Myovant Sciences's assets?
Raw Data
DB:71M PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.66
NYSE:MYOV Share Price * NYSE (2019-04-18) in USD $19.14
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:71M PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NYSE:MYOV Share Price ÷ Book Value per Share (both in USD)

= 19.14 ÷ 0.66

29x

* Primary Listing of Myovant Sciences.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Myovant Sciences is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Myovant Sciences's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Myovant Sciences has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Myovant Sciences expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
41.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Myovant Sciences expected to grow at an attractive rate?
  • Myovant Sciences's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Myovant Sciences's earnings growth is expected to exceed the Germany market average.
  • Unable to compare Myovant Sciences's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:71M Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:71M Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 41.1%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:71M Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:71M Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-03-31 1,055 513 1
2023-03-31 560 93 1
2022-03-31 160 -225 1
2021-03-31 7 -304 -298 2
2020-03-31 3 -301 -293 4
2019-03-31 0 -231 -270 4
DB:71M Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -206 -247
2018-09-30 -175 -218
2018-06-30 -135 -182
2018-03-31 -117 -143
2017-12-31 -93 -117
2017-09-30 -69 -83
2017-06-30 -45 -88
2017-03-31 -18 -83
2016-03-31 0 -10

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Myovant Sciences's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if Myovant Sciences is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:71M Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Myovant Sciences Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:71M Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-03-31 5.40 5.40 5.40 1.00
2023-03-31 1.00 1.00 1.00 1.00
2022-03-31 -2.50 -2.50 -2.50 1.00
2021-03-31 -3.43 -3.10 -3.76 2.00
2020-03-31 -3.95 -3.50 -4.37 4.00
2019-03-31 -4.09 -4.00 -4.25 5.00
DB:71M Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -3.84
2018-09-30 -3.50
2018-06-30 -3.01
2018-03-31 -2.41
2017-12-31 -1.97
2017-09-30 -1.43
2017-06-30 -1.63
2017-03-31 -1.70
2016-03-31 -0.27

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Myovant Sciences will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Myovant Sciences's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Myovant Sciences has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Myovant Sciences performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Myovant Sciences's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Myovant Sciences does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Myovant Sciences's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Myovant Sciences's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Myovant Sciences's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Myovant Sciences Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:71M Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -246.79 37.01 203.67
2018-09-30 -217.93 32.96 180.11
2018-06-30 -182.07 28.79 150.47
2018-03-31 -143.26 24.23 116.83
2017-12-31 -116.68 20.89 95.77
2017-09-30 -82.98 17.15 67.05
2017-06-30 -87.79 13.98 46.64
2017-03-31 -83.44 12.36 43.50
2016-03-31 -9.94 9.94

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Myovant Sciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Myovant Sciences has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Myovant Sciences improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Myovant Sciences's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Myovant Sciences has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Myovant Sciences's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Myovant Sciences's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Myovant Sciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Myovant Sciences's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Myovant Sciences's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Myovant Sciences Company Filings, last reported 3 months ago.

DB:71M Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 46.74 98.68 183.00
2018-09-30 74.10 44.56 154.32
2018-06-30 60.16 44.13 143.64
2018-03-31 37.73 43.62 108.62
2017-12-31 82.20 28.58 128.87
2017-09-30 118.72 0.00 129.33
2017-06-30 145.98 0.00 154.19
2017-03-31 166.78 0.00 180.84
2016-03-31 -0.22 0.00
  • Myovant Sciences's level of debt (211.1%) compared to net worth is high (greater than 40%).
  • Unable to establish if Myovant Sciences's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Myovant Sciences has less than a year of cash runway based on current free cash flow.
  • Myovant Sciences has less than a year of cash runway if free cash flow continues to grow at historical rates of 82% each year.
X
Financial health checks
We assess Myovant Sciences's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Myovant Sciences has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Myovant Sciences's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Myovant Sciences dividends. Estimated to be 0% next year.
If you bought €2,000 of Myovant Sciences shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Myovant Sciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Myovant Sciences's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:71M Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:71M Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-03-31
2023-03-31
2022-03-31
2021-03-31 0.00 1.00
2020-03-31 0.00 1.00
2019-03-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Myovant Sciences has not reported any payouts.
  • Unable to verify if Myovant Sciences's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Myovant Sciences's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Myovant Sciences has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Myovant Sciences's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Myovant Sciences's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Myovant Sciences afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Myovant Sciences has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Myovant Sciences's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Lynn Seely
COMPENSATION $12,159,234
AGE 59
TENURE AS CEO 2.9 years
CEO Bio

Dr. Lynn Seely, MD, serves as Principal Executive Officer at Myovant Sciences Ltd. and serves as its Executive Director. Dr. Seely has been the President and Chief Executive Officer of Myovant Sciences, Inc. since May 2016. She served as the Chief Medical Officer of Medivation, Inc. (formerly Orion Acquisition Corp. II) from May 9, 2005 to October 15, 2015 and served as its Consultant from October 15, 2015 to April 15, 2016. Dr. Seely was responsible for the strategy and execution of Orion Acquisition Corp. II's clinical development programs and for assisting in the evaluation of new opportunities to expand. She has more than 20 years of cross-functional expertise within the healthcare industry, including experience in clinical and product development, business development and regulatory affairs. Dr. Seely served as a Vice President of Clinical Development at Anesiva, Inc. (formerly, Corgentech Inc.), from September 2002 to 2005. At Corgentech, Dr. Seely was responsible for all aspects of a large Phase III cardiovascular trial of an E2F decoy and for the strategy and development of a second clinical program for another new chemical entity. Dr. Seely served as a Vice President of Clinical Development at Cytyc Health Corporation and ProDuct Health, Inc. from 2000 to 2001 and was responsible for clinical trial strategy and execution and physician training during commercialization of a novel breast cancer device. Dr. Seely served as a Vice President of Clinical Development for Cytyc Health Corporation's subsidiary of Cytyc Corporation from 2001 to 2002, where she assisted with transitional matters related to Cytyc Corporations acquisition of ProDuct Health, Inc. From 1996 to 2000, Dr. Seely served as an Associate Director of Clinical Development at Chiron Corporation, a biotechnology company where she served for more than four years in clinical development at Chiron Corporation and worked on a broad range of development programs in multiple different therapeutic areas. From July 1992 to November 1996, Dr. Seely served as an Assistant Professor of Medicine at the University of California, San Diego, where she ran a National Institute of Health-funded growth factor signal transduction laboratory and was co-director of the fellowship training program in Endocrinology and Metabolism. She has been a Director of Blueprint Medicines Corporation since April 15, 2016. After serving as Chief Resident in Medicine at Yale, she completed a post-doctoral fellowship in Endocrinology and Metabolism at the University of California, San Diego. Dr. Seely holds a B.A. in Journalism from the University of Oklahoma. Dr. Seely holds a Medical Degree from the University of Oklahoma College of Medicine and completed her residency in Internal Medicine at the Yale-New Haven Hospital in New Haven, Conn.

CEO Compensation
  • Lynn's compensation has increased whilst company is loss making.
  • Lynn's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Myovant Sciences management team in years:

1.8
Average Tenure
50
Average Age
  • The average tenure for the Myovant Sciences management team is less than 2 years, this suggests a new team.
Management Team

Lynn Seely

TITLE
Principal Executive Officer
COMPENSATION
$12M
AGE
59
TENURE
2.9 yrs

Frank Karbe

TITLE
Chief Financial Officer
COMPENSATION
$2M
AGE
50
TENURE
2.6 yrs

Matthew Lang

TITLE
General Counsel & Secretary
COMPENSATION
$3M
AGE
42

Julie Tran

TITLE
Senior Vice President of Human Resources

Marianne Romeo

TITLE
Head of Global Transactions & Risk Management
COMPENSATION
$221K
AGE
50
TENURE
3.2 yrs

Bryan Selby

TITLE
Senior Vice President of Product Development

Juan Camilo Ferreira

TITLE
Chief Medical Officer
AGE
48
TENURE
1.8 yrs

Teresa Perney

TITLE
Senior Vice President of Regulatory Affairs & Quality Assurance
TENURE
1.8 yrs

Andria Langenberg

TITLE
Head of Drug Safety & Pharmacovigilance
AGE
61
TENURE
1.8 yrs

Kim Sablich

TITLE
Chief Commercial Officer
TENURE
0.4 yrs
Board of Directors Tenure

Average tenure and age of the Myovant Sciences board of directors in years:

1.6
Average Tenure
56.5
Average Age
  • The average tenure for the Myovant Sciences board of directors is less than 3 years, this suggests a new board.
Board of Directors

Myrtle Potter

TITLE
Chairman of the Board
AGE
60
TENURE
0.4 yrs

Lynn Seely

TITLE
Principal Executive Officer
COMPENSATION
$12M
AGE
59
TENURE
2.9 yrs

Kathleen Sebelius

TITLE
Lead Independent Director
COMPENSATION
$343K
AGE
70
TENURE
0.8 yrs

Terrie Curran

TITLE
Independent Director
COMPENSATION
$338K
AGE
49
TENURE
2.4 yrs

Mark Guinan

TITLE
Independent Director
AGE
56
TENURE
0.8 yrs

Mark Altmeyer

TITLE
Non-Executive Director
COMPENSATION
$322K
AGE
57
TENURE
2.6 yrs

Vivek Ramaswamy

TITLE
Director
AGE
33
TENURE
2.6 yrs

Frank Torti

TITLE
Director
AGE
39
TENURE
0.4 yrs
Who owns this company?
Recent Insider Trading
  • Myovant Sciences insiders have only sold shares in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
20. Feb 19 Sell Juan Camilo Ferreira Individual 15. Feb 19 15. Feb 19 -260 €18.76 €-4,878
X
Management checks
We assess Myovant Sciences's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Myovant Sciences has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women’s health and endocrine diseases. The company’s lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of the hormonal preparation used in assisted reproduction. Myovant Sciences Ltd. has partnership with Flo Health to create a digital tool to screen for heavy menstrual bleeding. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was founded in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.

Details
Name: Myovant Sciences Ltd.
71M
Exchange: DB
Founded: 2016
$1,203,823,677
70,812,541
Website: http://myovant.com
Address: Myovant Sciences Ltd.
11-12 St. James’s Square,
Suite 1,
London,
Greater London, SW1Y 4LB,
United Kingdom
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NYSE MYOV Common Shares New York Stock Exchange US USD 27. Oct 2016
DB 71M Common Shares Deutsche Boerse AG DE EUR 27. Oct 2016
Number of employees
Current staff
Staff numbers
104
Myovant Sciences employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/22 22:31
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/15
Last earnings filing: 2019/02/07
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.